Valuation: Mezzion Pharma Co.,Ltd.

Capitalization 2,787B 1.91B 1.62B 1.49B 1.41B 2.61B 177B 2.65B 17.41B 6.83B 85.57B 7.16B 7.01B 302B P/E ratio 2024
-47.2x
P/E ratio 2025 -77.7x
Enterprise value 2,773B 1.9B 1.61B 1.48B 1.4B 2.6B 176B 2.64B 17.33B 6.79B 85.15B 7.12B 6.97B 300B EV / Sales 2024
104x
EV / Sales 2025 344x
Free-Float
71.64%
Yield 2024 *
-
Yield 2025 -
1 week+5.28%
Current month+5.89%
1 month+2.80%
3 months+3.03%
6 months+55.95%
Current year+1.78%
1 week 83,600
Extreme 83600
95,100
1 month 79,800
Extreme 79800
100,000
Current year 72,000
Extreme 72000
179,900
1 year 35,500
Extreme 35500
179,900
3 years 17,900
Extreme 17900
179,900
5 years 12,250
Extreme 12250
179,900
10 years 5,816.67
Extreme 5816.6667
179,900
Manager TitleAgeSince
Chief Executive Officer 69 2002-09-24
Corporate Officer/Principal - 2021-05-31
Comptroller/Controller/Auditor 71 2019-03-28
Director TitleAgeSince
Chairman 69 2002-09-24
Director/Board Member 70 -
Director/Board Member 65 2020-03-26
Change 5d. change 1-year change 3-years change Capi.($)
0.00%+5.28%+147.84%+410.29% 1.91B
+2.91%+5.95%+1.59%-28.18% 60.82B
-2.24%-3.88%+12.42%-20.31% 8.17B
+3.98%+2.17%+17.86%+92.47% 8.21B
-0.85%+7.11%+1.44%+44.13% 5.66B
-0.20%+4.95%-15.00%+76.20% 4.96B
+4.41%+1.40%+67.07%+39.84% 2.96B
-2.26%-0.41%-13.89%-37.73% 2.72B
-0.91%-1.55%+29.60%+28.93% 2.43B
-2.31%+1.48%+91.21%-1.65% 2.01B
Average +0.25%+2.45%+34.01%+60.40% 9.98B
Weighted average by Cap. +1.86%+4.27%+9.78%+3.72%

Financials

2024 2025
Net sales 8.61B 5.89M 4.99M 4.59M 4.35M 8.06M 545M 8.2M 53.81M 21.1M 264M 22.11M 21.65M 932M 7.91B 5.41M 4.59M 4.22M 3.99M 7.4M 501M 7.53M 49.42M 19.38M 243M 20.31M 19.89M 856M
Net income -19.48B -13.33M -11.29M -10.39M -9.83M -18.23M -1.23B -18.55M -122M -47.72M -598M -50.01M -48.97M -2.11B -34.93B -23.91M -20.25M -18.64M -17.64M -32.69M -2.21B -33.26M -218M -85.58M -1.07B -89.69M -87.82M -3.78B
Net Debt -27B -18.48M -15.66M -14.41M -13.63M -25.27M -1.71B -25.71M -169M -66.16M -829M -69.33M -67.89M -2.92B -13.7B -9.38M -7.94M -7.31M -6.92M -12.82M -868M -13.05M -85.61M -33.57M -421M -35.18M -34.45M -1.48B
Logo Mezzion Pharma Co.,Ltd.
Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
Employees
18
Date Price Change Volume
26-04-17 91,700.00 0.00% 91,464
26-04-16 91,700.00 -0.97% 132,637
26-04-15 92,600.00 +1.65% 153,340
26-04-14 91,100.00 +8.45% 212,457
26-04-13 84,000.00 -3.56% 149,971
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Equities
  3. A140410 Stock